When data were analyzed separately for study site clusters , a post hoc analysis demonstrated that both SPN-804 dosages were significantly superior to placebo in median percent seizure reduction ( placebo : -13.3 % ; 1200 mg : -34.5 % , P = 0.02 ; 2400 mg : -52.7 % , P = 0.006 ) in the North American study site cluster .